Genentech: Tarceva plus Avastin stalls lung cancer progression

02/3/2009 | Reuters

Genentech reported interim findings from a late-stage study showing that the combination of its drugs Avastin and Tarceva significantly prolonged survival in people with nonsmall-cell lung cancer without disease progression. The results prompted Genentech to halt the trial, indicating that the combination's "clinical benefit is likely quite significant," an analyst said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations